OrbiMed’s Nanobiotix NBTX Stock Holding History

OrbiMed’s Portfolio NBTX Stock Details NBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500,000	Closed	-$5.68M	–	169
2021 Q3	$5.68M	Hold	500,000	–	–	0.06%	150
2021 Q2	$6.89M	Hold	500,000	–	–	0.07%	141
2021 Q1	$7.52M	Hold	500,000	–	–	0.07%	130
2020 Q4	$8.25M	Buy	+500,000	New	+$8.61M	0.07%	128

Other funds holding NBTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

OrbiMed's NBTX Position: Q4 2021 in Review

OrbiMed sold out of Nanobiotix (NBTX) in Q4 2021, closing a stake of 500,000 shares — an estimated $5.68M sold.

OrbiMed first reported a position in NBTX in Q4 2020 and held it in 4 quarters. The position peaked at $8.25M in Q4 2020. 7 funds tracked by Wall St. Rank hold NBTX as of Q4 2021.

OrbiMed reported no remaining Nanobiotix position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 500,000 Nanobiotix shares in Q4 2021, an estimated $5.68M.
OrbiMed first reported a position in Nanobiotix in Q4 2020 and held it in 4 quarters.
OrbiMed's Nanobiotix position peaked at $8.25M in Q4 2020.
7 funds tracked by Wall St. Rank held Nanobiotix as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.